Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9209307 | 0.79 | SHBG (0.48) | SHBGEPHX1 | |
| SCHEMBL2342491 | 0.78 | SHBG (0.57) | SHBGEPHX1 | |
| SCHEMBL1094949 | 0.77 | SHBG (0.52) | SHBGEPHX1 | |
| SCHEMBL7761672 | 0.77 | SHBG (0.52) | SHBGEPHX1 | |
| SCHEMBL24659825 | 0.77 | SHBG (0.46) | SHBGEPHX1 | |
| SCHEMBL13678325 | 0.77 | SHBG (0.41) | SHBGEPHX1 | |
| SCHEMBL7089601 | 0.77 | SHBG (0.46) | SHBGEPHX1 | |
| SCHEMBL5400953 | 0.76 | SHBG (0.62) | SHBGEPHX1 | |
| SCHEMBL9207753 | 0.76 | SHBG (0.44) | SHBG | |
| SCHEMBL3632509 | 0.76 | SHBG (0.44) | SHBGEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2017-03-16 | — | — | US | disclosed |
| US-20150238492-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2015-08-27 | — | — | US | disclosed |
| US-9079912-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-07-14 | — | — | US | disclosed |
| US-8946245-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8933086-B2 | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140243360-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140018374-A1 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8541425-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243360-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | SHBG 4704/4885EPHX1 2386/4885 |
| US-20170071947-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | SHBG 4704/4885EPHX1 2386/4885 |
| US-20150238492-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | SHBG 4704/4885EPHX1 2386/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | SHBG 4712/4885EPHX1 2725/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | SHBG 4704/4885EPHX1 2386/4885 |
| US-20140018374-A1 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | SHBG 4704/4885EPHX1 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.